Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
NCT06653946

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Led by Kafrelsheikh University · Updated on 2024-10-29

716

Participants Needed

1

Research Sites

122 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.

CONDITIONS

Official Title

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Individuals of both genders aged 18 to 75 years
  • Acute first-ever embolic ischemic stroke
  • Diagnosis of atrial fibrillation
  • Eligible for thrombolysis treatment with alteplase
Not Eligible

You will not qualify if you...

  • Contraindications for alteplase treatment
  • Did not receive the full dose of alteplase
  • History of persistent or recurrent CNS disorders such as epilepsy, meningioma, or multiple sclerosis
  • Recurrent ischemic stroke diagnosed by clinical history or MRI
  • Symptoms of major organ failure, active cancer, or recent acute myocardial infarction within six weeks
  • Pregnant or lactating patients
  • Stroke due to venous thrombosis or following cardiac arrest

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt, 33511

Actively Recruiting

Loading map...

Research Team

M

mohamed G. Zeinhom, MD

CONTACT

S

sherihan R. ahmed, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here